Mit Ihrer Erlaubnis verwenden wir datenschutzfreundliche Analysen, um zu verstehen, welche Recherchewege funktionieren. Wir verwenden weder Werbe-Tracker noch Sitzungsaufzeichnungen. Sie können diese Auswahl in den Einstellungen ändern. Lesen Sie die Datenschutzerklärung.
Quote this valuation with its source: Fair value, Potential value and the price at analysis.
FAQ
REGN — frequently asked questions
Is Regeneron Pharmaceuticals Inc. overvalued?
In our latest published analysis dated 2026-05-10, REGN looks meaningfully undervalued. The price recorded at analysis is 715 USD versus our fair value of 1.210 USD; the high endpoint is presented separately as potential value of 1.505 USD. That implies roughly 69.2% upside to fair value at that date.
Our latest published report, analyzed 2026-05-10, gives REGN a fair value of 1.210 USD and a potential value of 1.505 USD. The conclusion is triangulated across multiple valuation models and weighted by reliability for Regeneron Pharmaceuticals Inc.'s archetype; it is a dated research output, not a live price.
Should I buy REGN now?
Our latest published rating for REGN, analyzed 2026-05-10, is Strong Buy. Regeneron Pharmaceuticals Inc. looks meaningfully undervalued at the analysis-date price of 715 USD versus fair value of 1.210 USD; potential value is 1.505 USD. This is research for educational purposes, not personalized investment advice.
What are the biggest risks for REGN?
The dedicated bear-case section in our report analyzed 2026-05-10 documents Regeneron Pharmaceuticals Inc.'s material risks, evidence, thresholds, and thesis-invalidation conditions. Scenario-specific explanations remain in that section so the report does not repeat or decontextualize them elsewhere.
What is REGN's rating?
Our latest published rating for REGN, analyzed 2026-05-10, is Strong Buy, with a published moat assessment of 9/10 (Wide). It reflects our fair value of 1.210 USD, the potential value of 1.505 USD, and the price recorded at analysis (715 USD).
Englische Quelle wird angezeigt, während wir übersetzen
Dieser Bericht wurde noch nicht übersetzt. Aktualisieren Sie in ein paar Minuten, sobald die Übersetzungswarteschlange aufgeholt hat.
§1 ZusammenfassungEN
30-Sekunden-AntwortStrong Buy
Preis im Verhältnis zum Wert
Kurs
$714.89
Fairer Wert
$1,209.72
Potenzialwert
$1,505.07
Stand
Kursdatum nicht erfasst
Warum es funktionieren kann
Bull: Dupixent dominates the immunology space longer than anticipated, and high-dose Eylea proves impenetrable to biosimilar erosion.
Was unsere Einschätzung ändern würde
High-Dose Eylea Fails to Defend Share: Vabysmo and early biosimilars rapidly erode Eylea's market dominance, cratering ophthalmology revenues before pipeline assets mature.
Regeneron is a high-quality mature biotechnology compounder with a strong core commercial portfolio (Dupixent, Eylea) and a proven R&D engine. Elevated near-term investments in pipeline and commercial capabilities have compressed margins, but offer a clear runway for long-term growth and diversification beyond its legacy blockbusters.
Regeneron is a high-quality mature biotechnology compounder with a strong core commercial portfolio (Dupixent, Eylea) and a proven R&D engine. Elevated near-term investments in pipeline and commercial capabilities have compressed margins, but offer a clear runway for long-term growth and diversification beyond its legacy blockbusters.
Patented core commercial assets in
Patented core commercial assets in Dupixent and Eylea generating sticky, recurring revenues.
VelociSuite R&D engine allowing highly
VelociSuite R&D engine allowing highly efficient discovery and commercialization timelines.
Cycle upside
Biotech enters a period of high M&A and pipeline validation; targeted biologics gain widespread formulary access and favorable pricing dynamics.
Hausempfehlung
Strong Buy. The downside is fundamentally fully priced in, while the long-term compounder cash profile remains robust and highly intact.
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions. It also offers EYLEA injections for wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; retinopathy of prematurity; Dupixent injection to treat atopic dermatitis and asthma; Libtayo injection for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection to treat heterozygous familial hypercholesterolemia (HoFH); and Kevzara solution for rheumatoid arthritis. It has license and collaboration agreement with Bayer for the development and commercialization of EYLEA 8 mg and EYLEA; Alnylam Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for diseases by addressing therapeutic disease targets expressed in the eye and central nervous system; Intellia Therapeutics, Inc. to advance CRISPR/Cas9 gene-editing technology for in vivo therapeutic development for therapies focused on neurological and muscular diseases; Hansoh Pharmaceuticals Group Company Limited to acquire development and commercial rights for HS-20094, a dual GLP-1/GIP receptor; and Tessera Therapeutics, Inc. develops and commercializes TSRA-196, an investigational gene editing therapy for Alpha-1 antitrypsin deficiency. Additionally, the company has a strategic collaboration with Telix Pharmaceuticals Limited to develop and commercialize radiopharmaceutical therapies. The company was incorporated in 1988 and is based in Tarrytown, New York.
§2 BärenszenarioEN
In a severe downside scenario, Regeneron faces simultaneous shocks: Eylea loses material share to Vabysmo and biosimilars, Dupixent growth sharply decelerates, and pipeline failures force a structural reset in operating margins below 25%. Even under these dire conditions, baseline FCFF generation anchors intrinsic value near $917, indicating the downside is already heavily priced in.
Dupixent hits an earlier-than-expected growth wall.
Operating margins structurally trapped below 25% due to pipeline failures.
In a downside event where core assets erode rapidly and R&D fails to deliver, the stock still holds a baseline value of $917, highlighting the massive margin of safety currently priced into the $714 level.
Wie diese These scheitern kann
High-Dose Eylea Fails to Defend Share
Low
Vabysmo and early biosimilars rapidly erode Eylea's market dominance, cratering ophthalmology revenues before pipeline assets mature.
FV impact
-25%
Dupixent Growth Wall
Medium
Dupixent matures faster than expected and label expansions underperform, halting the company's primary top-line engine.
FV impact
-15%
Frühwarnsignale zur Überwachung
Die fünf Entwicklungen, die unsere Anlagethese schwächen würden.
01
Eylea High-Dose Conversion Adoption
Failure of high-dose formulation to defend market share against biosimilars and competing bispecific therapies accelerates revenue erosion across core ophthalmology franchises, severely diminishing commercial cash generation.
Aktuell:Baseline adoption as of 2026-05-10
Alarm, wennStalls below 50.0% conversion rate across eligible patient populations over any twelve-month measurement window
02
§3 WettbewerbsgrabenEN
Wide
Patented core commercial assets in Dupixent and Eylea generating sticky, recurring revenues.
VelociSuite R&D engine allowing highly efficient discovery and commercialization timelines.
Scale advantages in manufacturing and clinical trial execution versus smaller biopharma peers.
Ökonomischer Gewinn
Economic profit is supported when reported returns exceed the company cost-of-capital hurdle.
9/ 10
Wide
Sources of advantage
01Patented core commercial assets in Dupixent and Eylea generating sticky, recurri — Patented core commercial assets in Dupixent and Eylea generating sticky, recurring revenues.Wide
02VelociSuite R&D engine allowing highly efficient discovery and commercialization — VelociSuite R&D engine allowing highly efficient discovery and commercialization timelines.Wide
03Scale advantages in manufacturing and clinical trial execution versus smaller bi — Scale advantages in manufacturing and clinical trial execution versus smaller biopharma peers.Wide
Bekannte Bedrohungen für den Wettbewerbsvorteil
Bedrohung
Schweregrad
Zeitrahmen
Minderung
Approaching patent cliffs and high-dose Eylea biosimilar threats.
medium
Monitor
Monitor the threat against the report checkpoints.
Competition from Roche/Genentech and targeted therapies like Vabysmo.
Dupixent dominates the immunology space longer than anticipated, and high-dose Eylea proves impenetrable to biosimilar erosion. Operating leverage drives margins past 35%, yielding an intrinsic value of $1,505.
If high-dose Eylea adoption beats internal valuation cross-checks, accumulate. If Dupixent volume misses, hold. If late-stage oncology pipeline data materially fails, trim position.
Im Plan
Hold
Auslöser: In-line results
If high-dose Eylea adoption beats internal valuation cross-checks, accumulate. If Dupixent volume misses, hold. If late-stage oncology pipeline data materially fails, trim position.
Verfehlt
Reassess
Auslöser: Downside surprise
If high-dose Eylea adoption beats internal valuation cross-checks, accumulate. If Dupixent volume misses, hold. If late-stage oncology pipeline data materially fails, trim position.
Ergebnisqualität
If high-dose Eylea adoption beats internal valuation cross-checks, accumulate. If Dupixent volume misses, hold. If late-stage oncology pipeline data materially fails, trim position.
Wichtige Kennzahlen vor dem Bericht
01
Kennzahl:
Eylea High-Dose Conversion Adoption
AktuellBaseline adoption as of 2026-05-10
Warum es wichtig ist
Warning level: Stalls below 50.0% conversion rate across eligible patient populations over any twelve-month measurement window. Failure of high-dose formulation to defend market share against biosimilars and competing bispecific therapies accelerates revenue erosion across core ophthalmology franchises, severely diminishing commercial cash generation.
REGN trades at 13.3x forward earnings against a peer median of 19.9x; EV/EBITDA of 15.2x against a peer median of 20.8x; 6 peers.
§10 Branche & ZyklusEN
Zyklusphase
Expansion
Current phase requires intensive capital deployment into next-gen pipeline indications to bridge the gap before legacy asset patent cliffs arrive.
Bullenzyklus
Biotech enters a period of high M&A and pipeline validation; targeted biologics gain widespread formulary access and favorable pricing dynamics.
Bärenzyklus
Regulatory pricing pressures compound with aggressive biosimilar substitution, severely discounting terminal multiples across mature biopharma.
Positionierung
Current phase requires intensive capital deployment into next-gen pipeline indications to bridge the gap before legacy asset patent cliffs arrive.
§11 PositionsmanagementEN
Positionsgröße
Core holding for large-cap growth allocations. Sizing should confidently reflect the robust margin of safety.
Risiko
Trim exposure if shares approach the $1,200 fair value mid-point, or if high-dose Eylea fails to retain 50%+ share over a 12-month trailing period.
Einstiegstranchen
Niveau
Aktion
Warum
Current / pullbacks
Accumulate aggressively at current levels ($714), as the market is overly penalizing transient R&D investments.
Accumulate aggressively at current levels ($714), as the market is overly penalizing transient R&D investments.
Ausstiegstranchen
Niveau
Aktion
Thesis break
Trim exposure if shares approach the $1,200 fair value mid-point, or if high-dose Eylea fails to retain 50%+ share over a 12-month trailing period.
§12 Investoren-PerspektivenEN
Bull view
Buy
Strong Buy. Regeneron is a high-quality mature compounder trading at a severe discount. Current pricing implies a nonsensical negative terminal growth rate, offering 69% upside to our $1,210 intrinsic value midpoint.
Base view
Buy
The 38.2% gap versus the $875.31 internal valuation cross-checks underscores a myopic market fixation on transient R&D spending and peak patent cliff fears, completely ignoring the underlying cash-generation power of VelociSuite.
§14 Endgültige EmpfehlungEN
Aktion
Starker Kauf
Strong Buy. Regeneron is a high-quality mature compounder trading at a severe discount. Current pricing implies a nonsensical negative terminal growth rate, offering 69% upside to our $1,210 intrinsic value midpoint.
Reassess the thesis against the named valuation, risk, and quarterly checkpoint evidence in this report.
§15Your notes
Capture your own thesis, position size, and follow-up questions. Stays on this device, only you can see it.
A permanent reduction in operating margins highlights structural cost inflation and heavier commercialization overhead, limiting operational leverage and depressing long-term free cash flow yield.
Aktuell:25.8% for the period ended 2025-12-31
Alarm, wennCompresses below 25.0% over any trailing twelve-month period
04
Late-Stage Clinical Asset Development
Repeated late-stage development setbacks in core oncology programs impair the research pipeline conversion thesis, destroying heavy capitalized investments without generating replacement revenue streams for maturing biologics.
Aktuell:$5.8B annual R&D spend as of 2026-05-10
Alarm, wennFiled clinical suspension or primary endpoint failure in two or more Phase 3 oncology trials within a 24-month window
A structural breakdown in capital returns below double digits confirms that massive research outlays are failing to generate adequate economic profits, impairing corporate compounding quality.
Aktuell:12.3% as of 2026-05-10
Alarm, wennBreaks below 10.0% as of any annual measurement date
Monitor
Monitor the threat against the report checkpoints.
Concentration risk given outsized revenue contribution from Dupixent.
medium
Monitor
Monitor the threat against the report checkpoints.
Our baseline assumes a successful transition from legacy assets to next-gen indications. Margins normalize to 30% as peak R&D spending subsides, anchoring fair value at $1,210 and bridging the gap from overly pessimistic internal valuation cross-checks.
Warning level: Compresses below 25.0% over any trailing twelve-month period. A permanent reduction in operating margins highlights structural cost inflation and heavier commercialization overhead, limiting operational leverage and depressing long-term free cash flow yield.
04
Kennzahl:
Late-Stage Clinical Asset Development
Aktuell$5.8B annual R&D spend as of 2026-05-10
Warum es wichtig ist
Warning level: Filed clinical suspension or primary endpoint failure in two or more Phase 3 oncology trials within a 24-month window. Repeated late-stage development setbacks in core oncology programs impair the research pipeline conversion thesis, destroying heavy capitalized investments without generating replacement revenue streams for maturing biologics.
Warning level: Breaks below 10.0% as of any annual measurement date. A structural breakdown in capital returns below double digits confirms that massive research outlays are failing to generate adequate economic profits, impairing corporate compounding quality.
